Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build

Core Insights - Guardant Health, Inc. is ranked fifth in a list of the Top 10 Oncology Stocks to Buy Now, indicating strong market interest and potential for growth [1] - Analysts from Stifel and Mizuho have raised their price targets for Guardant Health, with Stifel increasing it to $120 and Mizuho to $135, reflecting positive sentiment and expectations for future performance [2][3] Company Overview - Guardant Health, Inc. specializes in precision oncology, focusing on non-invasive liquid biopsy tests for cancer detection, treatment selection, and disease monitoring [3] - The company's flagship products, Guardant360 and Guardant Shield, facilitate early cancer detection, biomarker profiling, and real-time monitoring, which are essential for personalized cancer care [3] Market Expectations - Stifel anticipates strong volume and average selling price growth for Guardant Health in 2026, supported by publication and reimbursement events that are expected to maintain investor interest [1] - Mizuho has revised its models for the diagnostics and medical device sectors, indicating a broader positive outlook for the industry in which Guardant operates [2]